Open source Covid-19 vaccine PVX-001 started to try the first human

While the vaccine development process is carried out traditionally behind closed doors, the PVX-001 Covid-19 vaccine has reached clinical trial stage with the open source model of PopVax. This development shows that open collaboration approach in pharmaceutical industry started to give practical results.

The main features of PVX-001 are:

• Open source-based design: The formulation and development processes of the vaccine are open to the public, can be examined by researchers
• Faz 1 start: The evaluation of security and tollerability in human volunteers
• Speeded development: Fast progress is provided compared to the classic chart thanks to the community contribution and cooperation
• Global access goal: Open source model offers more affordable production in emerging countries

This approach, which offers alternative to vaccine projects carried out in control of traditional pharmaceutical companies or a single institution, opens doors to more collaboration between the scientists and the developers**. Open source philosophy provides quick bug detection and improvement mechanisms during the incubation period.

PVX-001 successfully entered Phase 1 trial, not only the progress of a vaccine candidate, but also is evidence of how effective weapons can be in the fight against pandemi.